Advanced search
1 file | 388.02 KB

Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: a single-arm phase II study (EORTC-08061)

Author
Organization
Keywords
Phase II study, Targeted therapy, Second-line treatment, CHEMOTHERAPY, MAINTENANCE SUNITINIB, Tyrosine kinase inhibitor, Sunitinib, SCLC

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 388.02 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Abdelraouf, Fatma, Egbert Smit, Baktiar Hasan, Jessica Menis, Sanjay Popat, Jan Van Meerbeeck, Veerle Surmont, Paul Baas, and Mary O’Brien. 2016. “Sunitinib (SU11248) in Patients with Chemo Naive Extensive Small Cell Lung Cancer or Who Have a ‘Chemosensitive’ Relapse: a Single-arm Phase II Study (EORTC-08061).” European Journal of Cancer 54: 35–39.
APA
Abdelraouf, F., Smit, E., Hasan, B., Menis, J., Popat, S., Van Meerbeeck, J., Surmont, V., et al. (2016). Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a “chemosensitive” relapse: a single-arm phase II study (EORTC-08061). EUROPEAN JOURNAL OF CANCER, 54, 35–39.
Vancouver
1.
Abdelraouf F, Smit E, Hasan B, Menis J, Popat S, Van Meerbeeck J, et al. Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a “chemosensitive” relapse: a single-arm phase II study (EORTC-08061). EUROPEAN JOURNAL OF CANCER. 2016;54:35–9.
MLA
Abdelraouf, Fatma, Egbert Smit, Baktiar Hasan, et al. “Sunitinib (SU11248) in Patients with Chemo Naive Extensive Small Cell Lung Cancer or Who Have a ‘Chemosensitive’ Relapse: a Single-arm Phase II Study (EORTC-08061).” EUROPEAN JOURNAL OF CANCER 54 (2016): 35–39. Print.
@article{7147042,
  author       = {Abdelraouf, Fatma and Smit, Egbert and Hasan, Baktiar and Menis, Jessica and Popat, Sanjay and Van Meerbeeck, Jan and Surmont, Veerle and Baas, Paul and O'Brien, Mary},
  issn         = {0959-8049},
  journal      = {EUROPEAN JOURNAL OF CANCER},
  keyword      = {Phase II study,Targeted therapy,Second-line treatment,CHEMOTHERAPY,MAINTENANCE SUNITINIB,Tyrosine kinase inhibitor,Sunitinib,SCLC},
  language     = {eng},
  pages        = {35--39},
  title        = {Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: a single-arm phase II study (EORTC-08061)},
  url          = {http://dx.doi.org/10.1016/j.ejca.2015.10.016},
  volume       = {54},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: